Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis

Journal of Crohn's and Colitis

Volumn 7, Issue 11, 2013, Pages

  Qiu, Xinyun ^a,c   Zhang, Mingming ^b   Yang, Xiaotong ^b   Hong, Na ^b   Yu, Chenggong ^b,c  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bifidobacterium longum; Faecalibacterium prausnitzii; Inflammatory bowel disease; Probiotic; Regulatory T cells

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2 RECEPTOR ALPHA; PROBIOTIC AGENT; RETINOID RELATED ORPHAN RECEPTOR GAMMA; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM; BODY WEIGHT; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; FAECALIBACTERIUM PRAUSNITZII; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; SPLEEN CELL; UPREGULATION; WEIGHT REDUCTION;

BIFIDOBACTERIUM LONGUM; FAECALIBACTERIUM PRAUSNITZII; INFLAMMATORY BOWEL DISEASE; PROBIOTIC; REGULATORY T CELLS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIFIDOBACTERIUM; BIOPSY, NEEDLE; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; PROBIOTICS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; T-LYMPHOCYTES, REGULATORY; TRINITROBENZENESULFONIC ACID; UP-REGULATION;

EID: 84884816918     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.04.002     Document Type: Article

References (40)

1. Kataria J., Li N., Wynn J.L., Neu J. Probiotic microbes: do they need to be alive to be beneficial?. Nutr Rev 2009, 67:546-550.
2. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273.
3. Tamboli C.P., Neut C., Desreumaux P., Colombel J.F. Dysbiosis in inflammatory bowel disease. Gut 2004, 53:1-4.
4. Louis P., Flint H.J. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009, 294:1-8.
5. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermudez-Humaran L.G., Gratadoux J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008, 105:16731-16736.
6. Machiels K., Joossens M., De Preter V., Arijs I., Ballet V., Organe S., et al. Association of Faecalibacterium Prausnitzii and Disease Activity in Ulcerative Colitis. Gastroenterology 2011, 140:S142.
7. Sokol H., Seksik P., Furet J.P., Firmesse O., Nion-Larmurier I., Beaugerie L., et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009, 15:1183-1189.
8. Machiels K., Joossens M., De P.V., Arijs I., Ballet V., Organe S., et al. Faecalibacterium prausnitzii is also reduced in ulcerative colitis. J Crohns Colitis 2011, 5:S166.
9. Olsen T., Rismo R., Cui G., Goll R., Christiansen I., Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011, 56:633-640.
10. Abad C., Gomariz R., Waschek J., Leceta J., Martinez C., Juarranz Y., et al. VIP in inflammatory bowel disease: state of the art. Endocr Metab Immune Disord Drug Targets 2012, 12:316-322.
11. Ogino H., Nakamura K., Ihara E., Akiho H., Takayanagi R. CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci 2011, 56:376-386.
12. Himmel M.E., Yao Y., Orban P.C., Steiner T.S., Levings M.K. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology 2012, 136:115-122.
13. Jianjun Z., Yali H., Zhiqun W., Mingming Z., Xia Z. Imbalance of T-cell transcription factors contributes to the Th1 type immunity predominant in pre-eclampsia. Am J Reprod Immunol 2010, 63:38-45.
14. Fuss I.J., Boirivant M., Lacy B., Strober W. The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol 2002, 168:900-908.
15. Bamias G., Corridoni D., Pizarro T.T., Cominelli F. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine 2012, 59:451-459.
16. Warren S., Ivan J.F. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1756-1767.
17. Ng S.C., Hart A.L., Kamm M.A., Stagg A.J., Knight S.C. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009, 15:300-310.
18. Foligne B., Nutten S., Grangette C., Dennin V., Goudercourt D., Poiret S., et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 2007, 13:236-243.
19. Drouault-Holowacz S., Foligne B., Dennin V., Goudercourt D., Terpend K., Burckel A., et al. Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolerance: in vitro and in vivo considerations. Clin Nutr 2006, 25:994-1003.
20. Dotan I., Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol 2005, 21:426-430.
21. Marcinkiewicz J., Ciszek M., Bobek M., Strus M., Heczko P.B., Kurnyta M., et al. Differential inflammatory mediator response in vitro from murine macrophages to lactobacilli and pathogenic intestinal bacteria. Int J Exp Pathol 2007, 88:155-164.
22. Lee H.S., Han S.Y., Bae E.A., Huh C.S., Ahn Y.T., Lee J.H., et al. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice. Int Immunopharmacol 2008, 8:574-580.
23. Philippe D., Heupel E., Blum-Sperisen S., Riedel C.U. Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. Int J Food Microbiol 2011, 149:45-49.
24. Di Sabatino A., Biancheri P., Rovedatti L., MacDonald T.T., Corazza G.R. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:368-371.
25. Zenewicz L.A., Antov A., Flavell R.A. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009, 15:199-207.
26. Fuss I.J., Boirivant M., Lacy B., Strober W. The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol 2002, 168:2063. [vol 168, pg 900, 2002].
27. Eastaff-Leung N., Mabarrack N., Barbour A., Cummins A., Barry S. Foxp3(+) regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010, 30:80-89.
28. Wang Y., Liu X.P., Zhi Z.B., Chen J.H., Yu C.G. Expression of CD4(+) forkhead box P3 (FOXP3)(+) regulatory T cells in inflammatory bowel disease. J Dig Dis 2011, 12:286-294.
29. Di Sabatino A., Biancheri P., Rovedatti L., MacDonald T.T., Corazza G.R. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:368-371.
30. Ogino H., Nakamura K., Ihara E., Akiho H., Takayanagi R. CD4(+)CD25(+) regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci 2011, 56:376-386.
31. Murai M., Turovskaya O., Kim G., Madan R., Karp C.L., Cheroutre H., et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009, 10:1178-1184.
32. Vale-Pereira S., Todo-Bom A., Geraldes L., Schmidt-Weber C., Akdis C.A., Mota-Pinto A. FoxP3, GATA-3 and T-bet expression in elderly asthma. Clin Exp Allergy 2011, 41:490-496.
33. Sakaguchi S., Powrie F. Emerging challenges in regulatory T cell function and biology. Science 2007, 317:627-629.
34. Liu H., Hu B., Xu D., Liew F.Y. CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol 2003, 171:5012-5017.
35. Uhlig H.H., Coombes J., Mottet C., Izcue A., Thompson C., Fanger A., et al. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 2006, 177:5852-5860.
36. Di Giacinto C., Marinaro M., Sanchez M., Strober W., Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 2005, 174:3237-3246.
37. Lorea Baroja M., Kirjavainen P., Hekmat S., Reid G. Anti-x2010;inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007, 149:470-479.
38. Pronio A., Montesani C., Butteroni C., Vecchione S., Mumolo G., Vestri A.R., et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 2008, 14:662-668.
39. Bi Y.J., Liu G.W., Yang R.F. Reciprocal modulation between TH17 and other helper T cell lineages. J Cell Physiol 2011, 226:8-13.
40. Geuking M.B., Cahenzli J., Lawson M.A., Ng D.C., Slack E., Hapfelmeier S., et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 2011, 34:794-806.